FGFR1 and breast cancer: A nonrandomized phase II trial of AZD4547 monotherapy is enrolling previously treated patients with FGFR1-amplified advanced squamous NSCLC (or FGFR1-amplified advanced breast cancer or FGFR2-amplified advanced esophagogastric cancer), with serial biopsies being performed to assess molecular effects (NCT01795768) 69.